The short version of lyophilization fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-11. Anything still debated is marked as such rather than presented as settled.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Alginate fiber, which is used in fabric, is usually produced through either microfluidic spinning, wet spinning, or electrospinning to obtain thinner fibers. Those fibers are used to produce alginate nonwoven fabric by carding and needle punching. The resulting felts are used in wound dressings, facial masks, and tissue scaffolds due to its hygroscopic and water retention ability.
There were a few similar spark discharge experiments contemporaneous with Miller–Urey. An article in The New York Times (March 8, 1953) titled "Looking Back Two Billion Years" describes the work of Wollman M. MacNevin at Ohio State University, before the Miller Science paper was published in May 1953. MacNevin was passing 100,000V sparks through methane and water vapor and produced "resinous solids" that were "too complex for analysis." Furthermore, K. A. Wilde submitted a manuscript to Science on December 15, 1952, before Miller submitted his paper to the same journal in February 1953. Wilde's work, published on July 10, 1953, used voltages up to only 600V on a binary mixture of carbon dioxide (CO2) and water in a flow system and did not note any significant reduction products. According to some, the reports of these experiments explain why Urey was rushing Miller's manuscript through Science and threatening to submit to the Journal of the American Chemical Society. By introducing an experimental framework to test prebiotic chemistry, the Miller–Urey experiment paved the way for future origin of life research. In 1961, Joan Oró produced milligrams of the nucleobase adenine from a concentrated solution of HCN and NH3 in water. Oró found that several amino acids were also formed from HCN and ammonia under those conditions. Experiments conducted later showed that the other RNA and DNA nucleobases could be obtained through simulated prebiotic chemistry with a reducing atmosphere.
== Production and development == Mulligan Stew was developed in early 1971 by the USDA Extension Service, and filmed by the USDA Motion Picture Service (which for many years prior produced educational cinematic films and TV programs for public viewing). Mulligan Stew was developed based on plan and design proposals by Developmental Committees, Iowa State University Extension Service 4-H Nutrition Television Programs. The Expanded Food and Nutrition Education Program (EFNEP) provided a grant to produce the series. (4-H is the official youth outreach and development program of the land-grant universities' Cooperative Extension Services and USDA.) The target audience of the program was older elementary school students, fourth through sixth grade. Eleanor Wilson, the national 4-H TV coordinator at the time, was tapped to be the series' technical advisor. Wilson subcontracted with Iowa State University to develop an outline of educational concepts for the series. USDA Extension then hired Ira Klugerman to direct the series. Klugerman, who came from a background of children's television at WQED in Pittsburgh, Pennsylvania, came up with the title and general treatment for the series. V. "Buddy" Renfro was the credited producer. Production began on location in southeast Washington, DC in 1971 (the opening sequence was filmed at RFK Stadium). Other filming locations included major production partner Michigan State University's home base of Lansing, Michigan, and on location for one episode at Johnson Space Center in Houston.
Sources: en.wikipedia.org
"Lidocaine Transdermal Patch". MedlinePlus. US patent 2441498, Nils Magnus Loefgren & Bengt Josef Lundqvist, "Alkyl glycinanilides", published 11 May 1948, issued 11 May 1948, assigned to ASTRA APOTEKARNES KEM FAB
The occupation directive JCS 1067, whose economic section had prohibited "steps looking toward the economic rehabilitation of Germany [or] designed to maintain or strengthen the German economy", is replaced by the new US occupation directive JCS 1779 which instead notes that "An orderly, prosperous Europe requires the economic contributions of a stable and productive Germany." August 14: Partition of India: Pakistan gains independence from the United Kingdom. August 15: Partition of India: India gains independence from the United Kingdom. September 9–10: Hong Kong conference: Nationalist groups rally around ex-emperor Bảo Đại, seeking an alternative solution for a non-communist Vietnam. September: The Soviet Union forms the Communist Information Bureau (COMINFORM) with which it dictates the actions of leaders and communist parties across its spheres of influence. October 20: Stanisław Mikołajczyk, leader of the non-communist Polish People's Party, flees the country ahead of impending arrest. Organized, legal political opposition to Polish communism is effectively at an end. November 14: The United Nations passes a resolution calling for the withdrawal of foreign soldiers from Korea, free elections in each of the two administrations, and the creation of a UN commission dedicated to the unification of the peninsula. November 29: The United Nations agrees to partition Palestine. November 30: The first phase of the 1948 Palestine war begins.
Before the ghetto riot of 1967, Detroit's black population had the highest rate of home-ownership of any black urban population in the country, and their unemployment rate was just 3.4 percent. It was not despairing that fueled the riot. It was the riot which marked the beginning of the decline of Detroit to its current state of despair. Detroit's population today is only half of what it once was, and its most productive people have been the ones who fled. However, Thomas Sugrue argues that over 20% of Detroit's adult black population was out of work in the 1950s and 1960s, along with 30% of black youth between eighteen and twenty-four. Economist Edward L. Glaeser believes the riots were a symptom of the city's already downward trajectory:
=== Complications === A number of complications may occur from cholecystitis if not detected early or properly treated. Signs of complications include high fever, shock and jaundice. Complications include the following:
Sources: en.wikipedia.org
== Medical uses == Oxazepam is an intermediate-acting benzodiazepine with a slow onset of action, so it is usually prescribed to individuals who have trouble staying asleep, rather than falling asleep. It is commonly prescribed for anxiety disorders with associated tension, irritability, and agitation. It is also prescribed for drug and alcohol withdrawal, and for anxiety associated with depression. Oxazepam is sometimes prescribed off-label to treat social phobia, post-traumatic stress disorder, insomnia, premenstrual syndrome, and other conditions.
== External links == Clinical trial number NCT02793128 for "The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus)" at ClinicalTrials.gov Clinical trial number NCT05243550 for "A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (ENVISION)" at ClinicalTrials.gov
Slow the Emergence of Resistant Bacteria and Prevent the Spread of Resistant Infections Strengthen National One-Health Surveillance Efforts to Combat Resistance Advance Development and use of Rapid and Innovative Diagnostic Tests for Identification and Characterization of Resistant Bacteria Accelerate Basic and Applied Research and Development for New Antibiotics, Other Therapeutics, and Vaccines Improve International Collaboration and Capacities for Antibiotic Resistance Prevention, Surveillance, Control and Antibiotic Research and Development The following are goals set to meet by 2020:
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.